Rebamipide, an amino acid derivative of 2-(1H)-quinolinone, is used for mucosal protection,[1] healing of gastroduodenal ulcers, and treatment of gastritis.[2] It works by enhancing mucosal defense, scavenging free radicals,[3] and temporarily activating genes encoding cyclooxygenase-2.[4]
 | |
| Clinical data | |
|---|---|
| Trade names | Mucosta (JP), Rebagen (KR, CN, IN), Rebagit (RU), Rebamax (ID) |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | By mouth (tablets) |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C19H15ClN2O4 |
| Molar mass | 370.79 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Studies have shown that rebamipide can fight the damaging effects of NSAIDs on the GIT mucosa,[5] and more recently, the small intestine, but not for naproxen-induced gastric damage.[6]
Availability
editRebamipide is used in a number of Asian countries including Japan (marketed as Mucosta), South Korea, China[7] and India (where it is marketed under the trade name Rebagen). It is also approved in Russia under the brand name Rebagit.[8]
Effects of this medicine
editThis medicine increases gastric mucosal prostaglandin E2, protects gastric mucosa, thereby suppresses gastric mucosal damage and increases gastric mucus secretion and gastric mucosal blood flow, to improve hemodynamic impairment, suppress inflammation and repair the gastric mucosa. It is usually used to treat gastric ulcer and improve gastric mucosal lesion (erosion, bleeding, redness and edema) in acute gastritis and acute exacerbation period of chronic gastritis.
References
edit- ^ Arakawa T, Kobayashi K, Yoshikawa T, Tarnawski A (September 1998). "Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing". Digestive Diseases and Sciences. 43 (9 Suppl): 5S – 13S. PMID 9753220.
- ^ Arakawa T, Watanabe T, Fukuda T, Yamasaki K, Kobayashi K (November 1995). "Rebamipide, novel prostaglandin-inducer accelerates healing and reduces relapse of acetic acid-induced rat gastric ulcer. Comparison with cimetidine". Digestive Diseases and Sciences. 40 (11): 2469–72. doi:10.1007/bf02063257. PMID 7587834. S2CID 22807270.
- ^ Takumida M, Anniko M (January 2009). "Radical scavengers for elderly patients with age-related hearing loss". Acta Oto-Laryngologica. 129 (1): 36–44. doi:10.1080/00016480802008215. PMID 18607930. S2CID 16906464.
- ^ Tarnawski AS, Chai J, Pai R, Chiou SK (February 2004). "Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action?". Digestive Diseases and Sciences. 49 (2): 202–9. doi:10.1023/b:ddas.0000017439.60943.5c. PMID 15104358. S2CID 31756608.
- ^ Zhang S, Qing Q, Bai Y, Mao H, Zhu W, Chen Q, Zhang Y, Chen Y (July 2013). "Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and meta-analysis". Digestive Diseases and Sciences. 58 (7): 1991–2000. doi:10.1007/s10620-013-2606-0. PMID 23456504. S2CID 4887031.
- ^ Gagliano-Jucá T, Moreno RA, Zaminelli T, Napolitano M, Magalhães AF, Carvalhaes A, Trevisan MS, Wallace JL, De Nucci G (June 2016). "Rebamipide does not protect against naproxen-induced gastric damage: a randomized double-blind controlled trial". BMC Gastroenterology. 16 (1): 58. doi:10.1186/s12876-016-0472-x. PMC 4893238. PMID 27259970.
- ^ "Rebamipide". Drugs.com.
- ^ "Registration Sertificate: Rebagit (rebamipide) Film-Coated Tablets" (in Russian). Russian State Register of Medicines. Retrieved 10 June 2017.
- Rebamipide Tablets 100mg "Kyorin", https://www.rad-ar.or.jp/siori/english/search/result?n=39008
 | This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |